• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $SBTX

    Silverback Therapeutics Inc.

    Subscribe to $SBTX
    $SBTX
    Specialty Chemicals
    Consumer Discretionary

    Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

    IPO Year: 2020

    Exchange: NASDAQ

    Website: silverbacktx.com

    Peers

    $APVO
    $CTMX
    $HARP
    $MRUS
    $ZYME

    Recent Analyst Ratings for Silverback Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    4/4/2022$25.00 → $3.50Buy → Neutral
    Goldman
    4/1/2022$25.00 → $1.80Outperform → Mkt Perform
    SVB Leerink
    4/1/2022$32.00 → $6.00Buy → Hold
    Stifel
    4/1/2022Buy → Neutral
    H.C. Wainwright
    11/12/2021$42.00 → $25.00Outperform
    SVB Leerink
    8/16/2021$46.00 → $49.00Outperform
    SVB Leerink
    See more ratings

    Silverback Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

      Data from Pivotal Clinical Trials to be Presented in Five Poster Presentations at the 2022 American College of Allergy, Asthma and Immunology Annual Scientific Meeting Data Support New Drug Application for neffy®, Currently Under Review with U.S. FDA SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) (ARS or the Company), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced that positive clinical data supporting neffy® (previously referred to as ARS-1), the potential first non-injectable medicine for treatment of alle

      11/10/22 8:00:00 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • ARS Pharmaceuticals Closes Merger with Silverback Therapeutics

      Over $280 Million in Combined Cash and Securities and at least Three Years Operating Runway to Support Launch and Commercialization of neffy® in the U.S., if Approved neffy® NDA Currently Under FDA Review; PDUFA Anticipated Mid-2023 MAA validated in the European Union Under Review SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) (ARS or the Company), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced the closing of its merger with Silverback Therapeutics, Inc. (Silverback). This follows the satisfaction of all cus

      11/8/22 4:02:00 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics, Inc. announces the FDA's acceptance of ARS Pharmaceuticals' NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis

      neffy has potential to be the first non-injectable medicine indicated to treat allergic reactions (type I) including anaphylaxis in the U.S., if approved Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback") today announced that the U.S. Food and Drug Administration (FDA) has accepted for review ARS Pharmaceuticals, Inc.'s (ARS Pharma) New Drug Application (NDA) for neffy for the emergency treatment of allergic reactions (type I) including anaphylaxis in adults and children ≥30 kg (66 lbs). If approved by the FDA, neffy would be the first non-injectable treatment available to patients with allergic reactions (type I) including anaphylaxis. The FDA has assigned a Prescription Drug U

      10/21/22 7:31:00 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Lifshitz Law PLLC Announces Investigations of SBTX, HNGR, PBFX, and IRBT

      NEW YORK, NY / ACCESSWIRE / August 6, 2022 /Silverback Therapeutics, Inc. (NASDAQ:SBTX)Lifshitz Law PLLC announces an investigation into possible breaches of fiduciary duty in connection with SBTX's merger with ARS Pharmaceuticals, Inc. Under Under the terms of the merger agreement, assuming that Silverback's net cash at closing is $240 million, SBTX's equity holders are expected to own approximately 37% of the combined company.If you are an SBTX investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or email at [email protected], Inc. (NYSE:HNGR)Lifshitz Law

      8/6/22 7:45:00 PM ET
      $HNGR
      $IRBT
      $PBFX
      $SBTX
      Medical Specialities
      Health Care
      Consumer Electronics/Appliances
      Consumer Discretionary
    • Silverback Therapeutics and ARS Pharmaceuticals Announce Merger

      Transaction to support potential commercialization of neffy™, ARS's needle-free epinephrine nasal spray Well-funded with at least three years of operating runway expected Companies to host conference call today, July 21, 2022, at 5:00 p.m. ET Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback") and ARS Pharmaceuticals, Inc. ("ARS") today announced that the companies have entered into a definitive agreement under which ARS will merge with Silverback in an all-stock transaction. The combined company will focus on the potential regulatory approval and commercialization of neffy, ARS's investigational epinephrine nasal spray for the treatment of Type I allergic reactions including anap

      7/21/22 4:00:00 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

      Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback"), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, today announced that Silverback management will participate in the H.C. Wainwright 24th Global Investment Conference from May 23-25, 2022. Laura Shawver, Ph.D., Silverback's Chief Executive Officer, will provide a corporate overview on Tuesday, May 24, 2022 at 7:00 AM ET / 4:00 AM PT. The webcast of the presentation will be available on Silverback's Investor Relations website for 30 days following the e

      5/17/22 4:05:00 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

      Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback"), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, today reported financial results for the first quarter ended March 31, 2022 and provided a business update. "In the first quarter of 2022, we have made significant progress in advancing the preclinical development of SBT8230, a first-in-class antibody-drug conjugate that we believe has the potential to drive functional cure in patients with chronic hepatitis B (cHBV) by eliciting a liver-localized anti-

      5/12/22 4:01:00 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results

      - Strategic realignment to focus resources on SBT8230 for chronic hepatitis B virus (cHBV) and discovery pipeline by discontinuing SBT6050 and SBT6290 clinical oncology programs - On track to complete a Phase 1 regulatory submission for SBT8230 in the fourth quarter of 2022 - Silverback to restructure workforce to support prioritized development, reduce operating expense, and extend cash runway - Estimated cash runway extended into the second half of 2026 Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback"), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chron

      3/31/22 4:00:00 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics to Present at the 42nd Annual Cowen Healthcare Conference

      Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback"), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that members of the Silverback management team will participate in the 42nd Annual Cowen Healthcare Conference from March 7-9, 2022. Laura Shawver, Ph.D., Silverback's Chief Executive Officer, will present a corporate overview on Wednesday, March 9th, 2022, at 12:50 p.m. ET (9:50 a.m. PT). The live webcast of the presentation will be available on Silverback's Investor Rela

      2/24/22 4:30:00 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

      Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback"), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that Silverback management will participate in the SVB Leerink 11th Annual Global Healthcare Conference from February 14-18, 2022. Laura Shawver, Ph.D., Silverback's Chief Executive Officer, and Valerie Odegard, Ph.D., Silverback's President and Chief Scientific Officer, will participate in a fireside chat on Wednesday, February 16th, 2022, at 1:00 PM ET (10:00 AM PT). The

      2/3/22 4:05:00 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary

    Silverback Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Silverback Therapeutics Inc. (Amendment)

      SC 13G/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

      2/9/24 8:35:56 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13D/A filed by Silverback Therapeutics Inc. (Amendment)

      SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

      9/25/23 4:30:47 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13D/A filed by Silverback Therapeutics Inc. (Amendment)

      SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

      9/1/23 4:15:58 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13D filed by Silverback Therapeutics Inc.

      SC 13D - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

      8/31/23 5:25:13 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Silverback Therapeutics Inc. (Amendment)

      SC 13G/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

      2/14/23 4:35:55 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Silverback Therapeutics Inc. (Amendment)

      SC 13G/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

      2/13/23 4:32:37 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Silverback Therapeutics Inc. (Amendment)

      SC 13G/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

      2/9/23 8:23:46 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13D/A filed by Silverback Therapeutics Inc. (Amendment)

      SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

      11/30/22 4:23:59 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13D filed by Silverback Therapeutics Inc.

      SC 13D - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

      11/21/22 4:07:53 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13D filed by Silverback Therapeutics Inc.

      SC 13D - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

      11/18/22 5:06:38 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary

    Silverback Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Silverback Therapeutics Announces the Appointment of Dr. Maria Koehler to its Board of Directors

      SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced the appointment of Maria Koehler, M.D., Ph.D. to Silverback’s Board of Directors. “On behalf of the board of directors and senior management team at Silverback, I am pleased to welcome Maria to the board,” said Peter Thompson, M.D., Co-founder and Chair of the Silverback Board of Directors. “Maria is an accomplished biopharmaceutical ve

      3/15/21 8:00:00 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary

    Silverback Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Silverback Therapeutics downgraded by Goldman with a new price target

      Goldman downgraded Silverback Therapeutics from Buy to Neutral and set a new price target of $3.50 from $25.00 previously

      4/4/22 7:33:52 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics downgraded by SVB Leerink with a new price target

      SVB Leerink downgraded Silverback Therapeutics from Outperform to Mkt Perform and set a new price target of $1.80 from $25.00 previously

      4/1/22 9:04:51 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics downgraded by Stifel with a new price target

      Stifel downgraded Silverback Therapeutics from Buy to Hold and set a new price target of $6.00 from $32.00 previously

      4/1/22 7:22:09 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Silverback Therapeutics from Buy to Neutral

      4/1/22 7:21:48 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SVB Leerink reiterated coverage on Silverback Therapeutics with a new price target

      SVB Leerink reiterated coverage of Silverback Therapeutics with a rating of Outperform and set a new price target of $25.00 from $42.00 previously

      11/12/21 7:03:12 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SVB Leerink reiterated coverage on Silverback Therapeutics with a new price target

      SVB Leerink reiterated coverage of Silverback Therapeutics with a rating of Outperform and set a new price target of $49.00 from $46.00 previously

      8/16/21 6:27:54 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • JonesTrading initiated coverage on Silverback Therapeutics with a new price target

      JonesTrading initiated coverage of Silverback Therapeutics with a rating of Buy and set a new price target of $50.00

      5/27/21 8:47:06 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SVB Leerink reiterated coverage on Silverback Therapeutics with a new price target

      SVB Leerink reiterated coverage of Silverback Therapeutics with a rating of Outperform and set a new price target of $46.00 from $49.00 previously

      5/17/21 6:19:07 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SVB Leerink reiterated coverage on Silverback Therapeutics with a new price target

      SVB Leerink reiterated coverage of Silverback Therapeutics with a rating of Outperform and set a new price target of $49.00 from $40.00 previously

      4/6/21 7:45:26 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Stifel reiterated coverage on Silverback Therapeutics with a new price target

      Stifel reiterated coverage of Silverback Therapeutics with a rating of Buy and set a new price target of $60.00 from $58.00 previously

      3/30/21 7:19:21 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary

    Silverback Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    Silverback Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • Lowenthal Richard E gifted 2,100,000 shares and received a gift of 2,100,000 shares, decreasing direct ownership by 20% to 4,126,822 units (SEC Form 4)

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      1/4/24 4:53:49 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4 filed by Karas Eric

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      1/4/24 4:47:38 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Tanimoto Sarina gifted 2,100,000 shares and received a gift of 2,100,000 shares, decreasing direct ownership by 24% to 3,276,854 units (SEC Form 4)

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      1/4/24 4:45:07 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4 filed by Dorsey Brian

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      1/4/24 4:42:31 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4 filed by Chakma Justin

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      1/4/24 4:41:27 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4 filed by Scott Kathleen D.

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      1/4/24 4:39:59 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4 filed by Fitzpatrick Alexander A

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      1/4/24 4:38:57 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Fitzpatrick Alexander A bought $319,954 worth of shares (86,258 units at $3.71), increasing direct ownership by 2,905% to 89,227 units (SEC Form 4)

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      10/2/23 4:23:09 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4: Ra Capital Management, L.P. bought $8,183,526 worth of shares (2,700,000 units at $3.03)

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      9/25/23 4:30:22 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4: Shawver Laura exercised 100,000 shares at a strike of $1.27 and sold $770,520 worth of shares (100,000 units at $7.71)

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      9/5/23 8:04:41 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics and ARS Pharmaceuticals Announce Merger

      Transaction to support potential commercialization of neffy™, ARS's needle-free epinephrine nasal spray Well-funded with at least three years of operating runway expected Companies to host conference call today, July 21, 2022, at 5:00 p.m. ET Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback") and ARS Pharmaceuticals, Inc. ("ARS") today announced that the companies have entered into a definitive agreement under which ARS will merge with Silverback in an all-stock transaction. The combined company will focus on the potential regulatory approval and commercialization of neffy, ARS's investigational epinephrine nasal spray for the treatment of Type I allergic reactions including anap

      7/21/22 4:00:00 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results

      - Strategic realignment to focus resources on SBT8230 for chronic hepatitis B virus (cHBV) and discovery pipeline by discontinuing SBT6050 and SBT6290 clinical oncology programs - On track to complete a Phase 1 regulatory submission for SBT8230 in the fourth quarter of 2022 - Silverback to restructure workforce to support prioritized development, reduce operating expense, and extend cash runway - Estimated cash runway extended into the second half of 2026 Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback"), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chron

      3/31/22 4:00:00 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics Presents Interim Clinical Results from the Ongoing Phase 1/1b Study of SBT6050 Alone or In Combination with Pembrolizumab in Patients with Advanced or Metastatic HER2-Expressing Solid Tumors

      – Proof-of-mechanism established with activation of myeloid and T/NK cells, and evidence of SBT6050 payload localization in the tumor microenvironment – – SBT6050 demonstrated a manageable safety profile with adverse events consistent with on-mechanism immune activation, both as a monotherapy or in combination with pembrolizumab – – Early signals of anti-tumor activity observed in a heavily pre-treated, heterogeneous population – – Management to host conference call today at 6:30 AM ET – Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback"), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissu

      9/16/21 3:30:00 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary

    Silverback Therapeutics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Fitzpatrick Alexander A bought $319,954 worth of shares (86,258 units at $3.71), increasing direct ownership by 2,905% to 89,227 units (SEC Form 4)

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      10/2/23 4:23:09 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4: Ra Capital Management, L.P. bought $8,183,526 worth of shares (2,700,000 units at $3.03)

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      9/25/23 4:30:22 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary

    Silverback Therapeutics Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by Silverback Therapeutics Inc.

      10-Q - ARS Pharmaceuticals, Inc. (0001671858) (Filer)

      11/9/23 4:04:53 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)

      11/9/23 4:02:29 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)

      9/25/23 4:17:04 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics Inc. filed SEC Form 8-K: Other Events

      8-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)

      9/20/23 6:05:01 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 144 filed by Silverback Therapeutics Inc.

      144 - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

      9/1/23 1:46:36 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 10-Q filed by Silverback Therapeutics Inc.

      10-Q - ARS Pharmaceuticals, Inc. (0001671858) (Filer)

      8/10/23 4:08:01 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)

      8/10/23 4:05:25 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 144 filed by Silverback Therapeutics Inc.

      144 - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

      8/1/23 5:16:09 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 144 filed by Silverback Therapeutics Inc.

      144 - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

      7/3/23 2:12:38 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)

      6/28/23 4:32:05 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary